OBJECTIVES: Cardiovascular diseases (CVDs) are responsible for one third of global deaths and the main cause of death among Jordanians. Pharmacist-led care outlined previously as a cost-effective approach in the management of chronic illness, however this is not well studied in low to middle income countries. This study aimed To assess the cost-effectiveness of pharmacist-led care versus usual care in preventing CVDs in Type 2 Diabetes Mellitus (T2DM).

METHODS: A Markov model of one year cycle length and 10-year time horizon was constructed to simulate 10-year CVD events, mortality and costs for two hypothetical cohorts; usual care and pharmacist-led care respectively of Jordanian patients suffering from T2DM. Public health provider perspective was adopted. Outcomes examined were incremental costs, LYGs, and incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analysis (PSA) assessed the robustness of the results.

RESULTS: The pharmacist-led care generated an additional 0.3 LYG/patient at an additional cost of JD1,238.78 (US$1,747.24) comparing to the usual care in the 10-year base-case analysis. Deterministic and PSA supported the robustness of base-case findings, indicating that pharmacist-led care is cost-effective.

CONCLUSIONS: The findings outline long-term clinical and economic benefits of expanding clinical pharmacist’s roles in direct patient care services.